Macquarie on Solara Pharma
Added to Asia Marquee Buy list
Catalyst: Vizag facility reaching optimal utilisation in 1QFY22, further clarity on Aurore merger synergy benefits
MS on AB Capital
OW, TP raised to Rs 158
PBT & PAT 19% & 30%, respectively, above MSe
Co seeing structural profitability expansion across biz
Conviction of it becoming a 15%+ annual compounder is rising; this, along with its parentage, make a potent combination for re-rating
CLSA on CIPLA
Weak quarter despite adjustments
Covid-19 products & monetisation of US inhaler pipeline key catalysts
Weak qtr with a miss across sales, Ebitda & net profit
Growth was rather muted across geographies
Raise 22-23CL EPS by 2-3%
CLSA on drreddys
Miss in 4Q but strong outlook
25% Ebitda margin goal achievable in 2-3yrs on sustainable basis (By FY24)
Strong performance in India, the EU and ROW & a steady quarter for the US
Raise our FY22/23CL EPS by 9%/15%
Escorts
CS: Demand bounceback in 2H + strong mid-term drivers of margin & market share gains
Medium-term strategy remains on track with focus on share gain in South, ramp up of capacity & boosting
exports through Kubota channel
Added to Asia Marquee Buy list
Catalyst: Vizag facility reaching optimal utilisation in 1QFY22, further clarity on Aurore merger synergy benefits
MS on AB Capital
OW, TP raised to Rs 158
PBT & PAT 19% & 30%, respectively, above MSe
Co seeing structural profitability expansion across biz
Conviction of it becoming a 15%+ annual compounder is rising; this, along with its parentage, make a potent combination for re-rating
CLSA on CIPLA
Weak quarter despite adjustments
Covid-19 products & monetisation of US inhaler pipeline key catalysts
Weak qtr with a miss across sales, Ebitda & net profit
Growth was rather muted across geographies
Raise 22-23CL EPS by 2-3%
CLSA on drreddys
Miss in 4Q but strong outlook
25% Ebitda margin goal achievable in 2-3yrs on sustainable basis (By FY24)
Strong performance in India, the EU and ROW & a steady quarter for the US
Raise our FY22/23CL EPS by 9%/15%
Escorts
CS: Demand bounceback in 2H + strong mid-term drivers of margin & market share gains
Medium-term strategy remains on track with focus on share gain in South, ramp up of capacity & boosting
exports through Kubota channel